Akari Therapeutics PLC (NASDAQ:AKTX) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Akari Therapeutics PLC (NASDAQ:AKTX) has been assigned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $32.33.

AKTX has been the topic of several analyst reports. Wall Street Zen upgraded shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 22nd. Alliance Global Partners upgraded Akari Therapeutics to a “strong-buy” rating in a report on Friday, September 18th. Maxim Group upgraded Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a report on Monday, July 20th. Finally, Weiss Ratings upgraded shares of Akari Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th.

Akari Therapeutics Stock Performance

AKTX opened at $9.81 on Tuesday. The stock’s fifty day simple moving average is $9.07 and its 200 day simple moving average is $9.03. Akari Therapeutics has a 1-year low of $3.02 and a 1-year high of $44.40.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases. The company’s research is focused on modulating the complement system and inflammatory pathways that contribute to tissue damage and disease progression.

Akari’s lead investigational product is nomacopan, a recombinant small protein originally derived from tick saliva. Nomacopan is designed to inhibit complement component C5 and leukotriene B4, two pathways involved in inflammation.